New STELARA® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
- Saturday, March 4, 2023, 7:03
- Finance
- Add a comment
Final cumulative pooled IBD safety data support the longstanding safety profile of STELARA across all IBD approved indications Additional long term extension data demonstrate more than half of STELARA-treated patients with ulcerative colitis achieved clinical remission, clinical response,…
About the Author
adminasapcorp has written 41532 stories on this site.